340 related articles for article (PubMed ID: 29164298)
1. Value of
Lv Z; Fan J; Xu J; Wu F; Huang Q; Guo M; Liao T; Liu S; Lan X; Liao S; Geng W; Jin Y
Eur J Nucl Med Mol Imaging; 2018 May; 45(5):735-750. PubMed ID: 29164298
[TBL] [Abstract][Full Text] [Related]
2. Relationship between 18F-FDG PET/CT radiometabolic markers and EGFR mutation, positive ALK Expression in patients with non-small cell lung cancer.
Gayaf M; Anar C; Aksel N; Erbaycu AE; Koporal H
Tuberk Toraks; 2021 Dec; 69(4):437-448. PubMed ID: 34957737
[TBL] [Abstract][Full Text] [Related]
3. Value of serum tumor markers for predicting EGFR mutations and positive ALK expression in 1089 Chinese non-small-cell lung cancer patients: A retrospective analysis.
Wang S; Ma P; Ma G; Lv Z; Wu F; Guo M; Li Y; Tan Q; Song S; Zhou E; Geng W; Duan Y; Li Y; Jin Y
Eur J Cancer; 2020 Jan; 124():1-14. PubMed ID: 31707279
[TBL] [Abstract][Full Text] [Related]
4. Correlation between combining
Ruan M; Liu L; Wang L; Lei B; Sun X; Chang C; Shen Y; Xie W
Eur J Nucl Med Mol Imaging; 2020 May; 47(5):1183-1197. PubMed ID: 31897590
[TBL] [Abstract][Full Text] [Related]
5. [Semiquantitative parameters of
Liao XH; Wang RF; Liu M; Chen XQ; Xiong Y; Nong L; Yin L; Zhang BY; DU YJ
Beijing Da Xue Xue Bao Yi Xue Ban; 2020 Oct; 53(2):246-254. PubMed ID: 33879893
[TBL] [Abstract][Full Text] [Related]
6. Predictive value of multiple metabolic and heterogeneity parameters of
Shi A; Wang J; Wang Y; Guo G; Fan C; Liu J
Ann Nucl Med; 2022 Apr; 36(4):393-400. PubMed ID: 35084711
[TBL] [Abstract][Full Text] [Related]
7. Role of [¹⁸F]FDG PET in prediction of KRAS and EGFR mutation status in patients with advanced non-small-cell lung cancer.
Caicedo C; Garcia-Velloso MJ; Lozano MD; Labiano T; Vigil Diaz C; Lopez-Picazo JM; Gurpide A; Zulueta JJ; Richter Echevarria JA; Perez Gracia JL
Eur J Nucl Med Mol Imaging; 2014 Nov; 41(11):2058-65. PubMed ID: 24990403
[TBL] [Abstract][Full Text] [Related]
8. Role of 18F-fluorodeoxyglucose positron emission tomography in predicting epidermal growth factor receptor mutations in non-small cell lung cancer.
Mak RH; Digumarthy SR; Muzikansky A; Engelman JA; Shepard JA; Choi NC; Sequist LV
Oncologist; 2011; 16(3):319-26. PubMed ID: 21339258
[TBL] [Abstract][Full Text] [Related]
9. CT features associated with EGFR mutations and ALK positivity in patients with multiple primary lung adenocarcinomas.
Han X; Fan J; Gu J; Li Y; Yang M; Liu T; Li N; Zeng W; Shi H
Cancer Imaging; 2020 Jul; 20(1):51. PubMed ID: 32690092
[TBL] [Abstract][Full Text] [Related]
10. The relationship of PET/CT SUVmax with EGFR mutation status and ALK rearrangement in lung adenocarcinoma.
Igde MH; Ozturk A; Oruc O; Oztas S; Kavas M
Hell J Nucl Med; 2022; 25(2):188-195. PubMed ID: 36030461
[TBL] [Abstract][Full Text] [Related]
11. EGFR mutation decreases FDG uptake in non‑small cell lung cancer via the NOX4/ROS/GLUT1 axis.
Chen L; Zhou Y; Tang X; Yang C; Tian Y; Xie R; Chen T; Yang J; Jing M; Chen F; Wang C; Sun H; Huang Y
Int J Oncol; 2019 Jan; 54(1):370-380. PubMed ID: 30431083
[TBL] [Abstract][Full Text] [Related]
12. Effects of cigarette smoking on metabolic activity of lung cancer on baseline
Jiang M; Guo X; Zhang X; Gao Q; Mei W; Zhang J; Zheng J
PeerJ; 2022; 10():e13352. PubMed ID: 35497180
[TBL] [Abstract][Full Text] [Related]
13. Exploring the correlation between HER2 alterations and
Ruan M; Chang C; Sun J; Liu L; Wang L; Lei B; Yan H; Zhang H; Xie W; Wang Y
J Cancer Res Clin Oncol; 2023 Nov; 149(16):14493-14507. PubMed ID: 37572120
[TBL] [Abstract][Full Text] [Related]
14. Value of ¹⁸F-FDG uptake on PET/CT and CEA level to predict epidermal growth factor receptor mutations in pulmonary adenocarcinoma.
Ko KH; Hsu HH; Huang TW; Gao HW; Shen DH; Chang WC; Hsu YC; Chang TH; Chu CM; Ho CL; Chang H
Eur J Nucl Med Mol Imaging; 2014 Oct; 41(10):1889-97. PubMed ID: 24852187
[TBL] [Abstract][Full Text] [Related]
15. Volumetric PET parameters can predict overall survival in advanced lung adenocarcinoma.
Yanarateş A; Yazici B
Rev Esp Med Nucl Imagen Mol (Engl Ed); 2020; 39(1):3-8. PubMed ID: 31818695
[TBL] [Abstract][Full Text] [Related]
16. 18F-FDG uptake for prediction EGFR mutation status in non-small cell lung cancer.
Guan J; Xiao NJ; Chen M; Zhou WL; Zhang YW; Wang S; Dai YM; Li L; Zhang Y; Li QY; Li XZ; Yang M; Wu HB; Chen LH; Liu LY
Medicine (Baltimore); 2016 Jul; 95(30):e4421. PubMed ID: 27472739
[TBL] [Abstract][Full Text] [Related]
17. [Value of (18)F-FDG PET-CT imaging to predict epidermal growth factor receptor mutations in patients with lung squamous cell carcinoma].
Zhao CY; Deng XY; Wang HS; Cao GP; Ding JN; Ding CY
Zhonghua Zhong Liu Za Zhi; 2021 Jul; 43(7):795-800. PubMed ID: 34289575
[No Abstract] [Full Text] [Related]
18. Correlation between EGFR mutation status and F
Zhu L; Yin G; Chen W; Li X; Yu X; Zhu X; Jiang W; Jia C; Chen P; Zhang Y; Lu D; Yu L; Li X; Xu W
Thorac Cancer; 2019 Apr; 10(4):659-664. PubMed ID: 30776196
[TBL] [Abstract][Full Text] [Related]
19. IMPORTANCE of PRETREATMENT 18F-FDG PET/CT TEXTURE ANALYSIS in PREDICTING EGFR and ALK MUTATION in PATIENTS with NON-SMALL CELL LUNG CANCER.
Agüloğlu N; Aksu A; Akyol M; Katgı N; Doksöz TÇ
Nuklearmedizin; 2022 Dec; 61(6):433-439. PubMed ID: 35977671
[TBL] [Abstract][Full Text] [Related]
20. [Evaluate the value of (18)F-FDG PET-CT imaging in predicting the mutationsin epidermal growth factor receptor in lung adenocarcinoma].
Ding CY; Yang WP; Guo Z; Sun J; Li YY; Li TR
Zhonghua Zhong Liu Za Zhi; 2017 Jul; 39(7):528-531. PubMed ID: 28728300
[No Abstract] [Full Text] [Related]
[Next] [New Search]